These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11773917)

  • 1. Pharmacodynamic profile of short-term readministration of abciximab in healthy subjects.
    Freedman J; Mascelli MA; Pezzullo JC; Barnathan ES; Frederick B; Jordan RE; Abernethy DR
    Am Heart J; 2002 Jan; 143(1):87-94. PubMed ID: 11773917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
    Mascelli MA; Kleiman NS; Marciniak SJ; Damaraju L; Weisman HF; Jordan RE
    Am Heart J; 2000 Apr; 139(4):696-703. PubMed ID: 10740154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
    Mascelli MA; Worley S; Veriabo NJ; Lance ET; Mack S; Schaible T; Weisman HF; Jordan RE
    Circulation; 1997 Dec; 96(11):3860-6. PubMed ID: 9403608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention.
    Kereiakes DJ; Runyon JP; Kleiman NS; Higby NA; Anderson LC; Hantsbarger G; McDonald S; Anders RJ
    Circulation; 1996 Sep; 94(5):906-10. PubMed ID: 8790024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.
    Mascelli MA; Lance ET; Damaraju L; Wagner CL; Weisman HF; Jordan RE
    Circulation; 1998 May; 97(17):1680-8. PubMed ID: 9591761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM337) in healthy subjects.
    Harder S; Kirchmaier CM; Krzywanek HJ; Westrup D; Bae JW; Breddin HK
    Circulation; 1999 Sep; 100(11):1175-81. PubMed ID: 10484537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine.
    Peter K; Kohler B; Straub A; Ruef J; Moser M; Nordt T; Olschewski M; Ohman ME; Kübler W; Bode C
    Circulation; 2000 Sep; 102(13):1490-6. PubMed ID: 11004138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment.
    Kereiakes DJ; Kleiman N; Ferguson JJ; Runyon JP; Broderick TM; Higby NA; Martin LH; Hantsbarger G; McDonald S; Anders RJ
    Circulation; 1997 Aug; 96(4):1117-21. PubMed ID: 9286938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects.
    Abernethy DR; Pezzullo J; Mascelli MA; Frederick B; Kleiman NS; Freedman J
    Clin Pharmacol Ther; 2002 Mar; 71(3):186-95. PubMed ID: 11907493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP; Schuster P
    Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
    Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid platelet-function assay: an automated and quantitative cartridge-based method.
    Smith JW; Steinhubl SR; Lincoff AM; Coleman JC; Lee TT; Hillman RS; Coller BS
    Circulation; 1999 Feb; 99(5):620-5. PubMed ID: 9950658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
    Quinn MJ; Murphy RT; Dooley M; Foley JB; Fitzgerald DJ
    J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of abciximab induced platelet blockade using a rapid point of care assay.
    Kereiakes DJ; Mueller M; Howard W; Lacock P; Anderson LC; Broderick TM; Roth EM; Whang DD; Abbottsmith CW
    J Thromb Thrombolysis; 1999 Jun; 7(3):265-76. PubMed ID: 10375388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ
    Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2003 Feb; 145(2):e6. PubMed ID: 12595861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention.
    Madan M; Berkowitz SD; Christie DJ; Jennings LK; Smit AC; Sigmon KN; Glazer S; Tcheng JE
    Am Heart J; 2001 Feb; 141(2):226-33. PubMed ID: 11174336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
    Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.